Interestingly, we have observed that unlike FAK in cancer cells, FAK in vascular smooth muscle cells (VSMCs) in vivo is predominantly in the nucleus and does not appear to be active14, suggesting that cancer cells may use unknown mechanisms to promote nuclear FAK activity. This evidence concerns the gene PTK2 and cancer.